1. Introduction {#sec0005}
===============

*Nidoviruses* are important pathogens of both humans and livestock; they are enveloped, plus-strand RNA viruses comprising the families *Arteriviridae* and *Coronaviridae* ([@bib0040]). Porcine reproductive and respiratory syndrome virus (PRRSV), a member of the family *Arteriviridae* ([@bib0105]), has been a major threat to the worldwide swine industry since its discovery in the early 1990s ([@bib0155], [@bib0010]). In 2006, a highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV) emerged and prevailed in mainland China, resulting in devastating damage to swine production ([@bib0120]). Currently, HP-PRRSV causes high morbidity and high mortality in infected pigs of all ages and has remained a major threat to the swine producers in China and surrounding countries ([@bib0045]). Porcine epidemic diarrhea virus (PEDV), a member of the genus *Alpha-coronavirus* ([@bib0110]), was first identified in the 1980s in China ([@bib0160]). PEDV causes a contagious intestinal disease called porcine epidemic diarrhea (PED), which is characterized by vomiting, diarrhea, and dehydration ([@bib0145]). In October 2010, a large-scale outbreak of PED caused by a PEDV variant occurred in China, resulting in tremendous economic losses ([@bib0085], [@bib0140], [@bib0145], [@bib0130]). PRRSV and PEDV are highly virulent and contagious porcine pathogens that cause respiratory and enteric disease in pigs and result in significant economic losses for the intensive pig production worldwide ([@bib0085], [@bib0105], [@bib0145]).

In the PRRSV and PEDV genome, ORF1a and ORF1b comprise approximately 80% of the genome and encode polyproteins (pp1a and pp1b) that are cleaved by viral proteases into intermediate and mature nonstructural proteins ([@bib0175], [@bib0040]). The viral proteases involved in polyprotein cleavage are papain-like proteases (PL1pro and PL2pro) and a 3CL serine protease (PRRSV nsp4; 3CLSP)/3C-like (PEDV nsp5; 3CL) protease ([@bib0125], [@bib0170]). During replication, the PL1pro and PL2pro proteases cleave the N-proximal region of pp1a/pp1ab, and the 3CLSP/3CL protease cleaves the viral polyprotein at other conserved inter-domain junctions ([@bib0125], [@bib0170]). The viral 3CLSP/3CL proteases play an essential role in *artertivirus* and *coronavirus* replication; therefore, they have received much attention as potential key antiviral targets (including TGEV, FIPV, IBV and SARS-CoV) ([@bib0005], [@bib0060], [@bib0075], [@bib0165]).

As RNA viruses, PRRSV and PEDV are prone to mutation under selective pressures in the field, and this may cause the frequent appearances of new variant strains ([@bib0145], [@bib0045]). Moreover, current commercial vaccination approaches against PRRSV and PEDV are only partially effective ([@bib0145], [@bib0025], [@bib0030]). To date, effective broad-spectrum antiviral drugs for PRRSV and PEDV infections are not available, although antiviral compounds have been reported previously ([@bib0050], [@bib0115], [@bib0035]). This remains an impediment to identifying new inhibitors that target the PRRSV and PEDV 3CLSP/3CL proteases for use as antiviral therapies during disease epidemics. In this study, our findings provide new insights into the molecular mechanisms underlying 3CLSP or 3CL protease-mediated inhibition of viral replication and may also guide the development of new broad-spectrum antiviral drugs.

2. Materials and methods {#sec0010}
========================

2.1. Compounds {#sec0015}
--------------

A low-molecular-weight fragment-based library containing approximately 1000 compounds (Specs, Delf, Netherlands) was used for antiviral fragment screening. These fragments are defined as small molecules obeying the Congreve 'Rule of three' in which molecular weight (MW) ≤ 300, the number of hydrogen donors and acceptors ≤ 3 and cLogP ≤ 3 ([@bib0015]). All these compounds were dissolved in dimethyl sulfoxide (DMSO; Mpbio) at a concentration of 10 mM. Moreover, compounds 1--5 were prepared in DMSO as stock solutions (50 mM).

2.2. Viruses and cells {#sec0020}
----------------------

Marc-145 cells (a PRRSV-permissive cell line derived from MA-104 cells) ([@bib0055]) and African green monkey cells (Vero cells; Cat. No. CCL-81) were cultured in Dulbecco's minimum essential medium (DMEM, HyClone), supplemented with 10% fetal bovine serum (Gibco) at 37 °C with 5% CO~2~. Moreover, the HP-PRRSV WUH3 strain (GenBank accession no. [HM853673](ncbi-n:HM853673){#intr0005}) ([@bib0080]) and the PEDV FJZZ strain (GenBank: [KC140102.1](ncbi-n:KC140102.1){#intr0010}) were used in all assays.

2.3. Expression and purification of PRRSV nsp4 (3CLSP) and PEDV nsp5 (3CL protease) {#sec0025}
-----------------------------------------------------------------------------------

For expression of PRRSV 3CLSP, the coding sequence was PCR-amplified from the PRRSV WUH3 strain cDNA library and inserted into pET-42b (+) with a C-terminal His~6~-tag at the *NdeI* and *BamHI* restriction sites. All constructs were validated by DNA sequencing. The plasmid was transformed into *Escherichia coli* strain BL21(DE3), and cells were cultured at 37 °C in LB medium containing 50 mg/l kanamycin. When the optical density at 600-nm (OD~600~) reached 0.8, the culture was cooled to 18 °C and supplemented with 0.8 mM IPTG (isopropyl\--[d]{.smallcaps}-thiogalactopyranoside). After overnight induction, the cells were harvested via centrifugation at 8500 rpm (30 min, 4 °C). Protein purification followed our previously reported procedure ([@bib0100]). Finally, the harvested protein was concentrated to a volume of approximately 2.0 ml and filtered using a Superdex 200 gel filtration column (GE Healthcare) equilibrated with buffer (20 mM Tris--HCl and 200 mM NaCl, pH 7.4). The concentration of the purified protein was determined by detecting the absorbance at 280-nm (A280) using a NanoDrop 2000c UV--vis spectrophotometer (Thermo Fisher Scientific). PEDV 3CL protease expression and purification were carried out following our previously reported procedure ([@bib0170]).

2.4. Measurement of IC~50~ {#sec0030}
--------------------------

The polypeptide substrate Dabsyl-KTAYFQLE↓GRHFE-Edans ([@bib0125]) and Dabcyl-YNSTLQ↓AGLRKM-E-Edans ([@bib0170]) were chemically synthesized by the GenScript Corporation. PRRSV 3CLSP and PEDV 3CL proteases were used at a final concentration of 2 μM and 0.25 μM, respectively. Compounds at various concentrations (6.25--500 μM) were pre-incubated with protease for 20 min at 37 °C, and 1 μM (3CLSP substrate) or 10 μM (3CL protease substrate) was added to the mixture in a black 96-well plate. The mixtures were then further incubated at 37 °C for 60 min, and enhanced fluorescence due to substrate cleavage by 3CLSP/3CL protease was monitored at 340 excitation and 485 emission. The relative fluorescence units (RFU) were calculated by subtracting the background (substrate control well without protease) from the fluorescence readings. The percentage of inhibition was calculated as follows: Percentage of inhibition (%) = 100 × \[1 − RFU of the experimental group (60 min-- 0 min)/RFU of the control group (60 min--0 min)\].

2.5. Cell viability assay {#sec0035}
-------------------------

The 50% cell death toxic concentrations (CC~50~) of compounds 2, 3 and 5 in MARC-145 cells and Vero cells were determined following our previously reported procedure ([@bib0100]). Briefly, confluent cells grown in white 96-well plates (Corning, Tewksbury, MA, USA) were treated with various concentrations (50--500 μM) of compounds for 72 h. MARC-145 cells or Vero cells were treated with 0.1% DMSO as control. Cell cytotoxicity was measured using the Celltiter-Glo Luminescent Cell Viability Assay reagent (Promega, Madison, WI, USA).

2.6. TCID~50~ assay for PRRSV and PEDV {#sec0040}
--------------------------------------

MARC-145 cells were seeded in 12-well plates at a density of 2.5 × 10^5^ cells per well. When cells were grown to 70--80% confluence, PRRSV was added with increasing concentrations of compounds 2, 3 and 5 (6.25 μM, 12.5 μM, 25 μM, 50 μM, 100 μM and 200 μM) at a multiplicity of infection (MOI) of 0.1, and then supernatants containing virus and compounds were used to infect MARC-145 cells for 36 h. Then, the harvested supernatant (include PRRSV and compounds) was used for TCID~50~ assays. Briefly, MARC-145 cells were seeded in 96-well plates, and infected with serial 10-fold dilutions of supernatant using eight replicates in TCID~50~ assays. The plates were incubated for 72--96 h before viral titers were calculated. The TCID~50~ assay for PEDV was also performed following the same methods.

2.7. Western blot analysis {#sec0045}
--------------------------

MARC-145 cells or Vero cells were seeded in 6-well plates at a density of 5 × 10^5^--1 × 10^6^ cells per well. When cells were grown to 70--80% confluence, the PRRSV WUH3 strain and the PEDV FJZZ strain were inoculated into cells at an MOI of 0.1. Virus-infected cells were incubated in the presence of compounds (6.25 μM, 12.5 μM, 25 μM, 50 μM, 100 μM and 200 μM) for up to 36 h. Then, compound-treated PRRSV/PEDV-infected or control cells (0.4% DMSO) were lysed in a lysis buffer (20 mM Tris \[pH 7.5\], 150 mM NaCl, 1% Triton X-100) containing proteinase inhibitors (Beyotime). Supernatants were harvested, and the total protein for each sample was measured using a BCA protein assay kit (Thermo Scientific). Equal amounts of protein for each sample were analyzed by performing 12% SDS-PAGE followed by transfer to PVDF membranes (Bio-Rad). After blocking, the membranes were incubated overnight at 4 °C with an anti-PRRSV/PEDV nucleocapsid (N) protein monoclonal antibody (1:3000) and an anti-GAPDH monoclonal antibody (1:5000; Proteintech). Finally, the membranes were incubated with goat-anti-mouse secondary antibody (Boster Biological Technology Co., Ltd.) for 1 h (1:5000). Then, the membranes were visualized using an enhanced chemiluminescence system (Amersham Imager 600, GE Healthcare). Densitometry analysis of the levels of nucleocapsid protein levels have been measured by Image J software, and normalized to GAPDH.

2.8. In silico docking {#sec0050}
----------------------

The crystal structures of PRRSV nsp4 (3CLSP, PDB: [5Y4L](pdb:5Y4L){#intr0015}) and PEDV nsp5 (3CL protease, PDB: [4XFQ](pdb:4XFQ){#intr0020}) and the complex structure of PEDV nsp5 (3CL protease, PDB: [4ZUH](pdb:4ZUH){#intr0025}) were retrieved. Homology models of PRRSV nsp4 and PEDV nsp5 with compounds 2 and 3 were generated using Autodock 4 software. The root mean square deviation (RMSD) and the most likely binding pattern were analyzed using PDBeFold (<http://pdbe.org/fold/>) and PyMOL (Schrödinger), respectively. The amino acid sequences of *Arterivirus* (PRRSV and EAV) 3CLSP and PEDV 3CL protease were aligned using ClustalW2 ([@bib0070]) and visualized with the ESPript 3.0 server (<http://espript.ibcp.fr>) ([@bib0095]).

2.9. Statistical analysis {#sec0055}
-------------------------

IC~50~, CC~50~ and EC~50~ were determined using GraphPad Prism software 5 (GraphPad Software, San Diego, CA). All experiments were performed in triplicate, and values (±standard deviations \[SD\]) are shown. Significant differences were determined using Student's *t*-test. \*, P \< 0.05 (considered significant compared with control group); \*\*, P \< 0.01 (considered highly significant); \*\*\*, P \< 0.001 (considered extremely significant).

3. Results {#sec0060}
==========

3.1. Identification of inhibitors that target PRRSV nsp4 (3CLSP) {#sec0065}
----------------------------------------------------------------

A library of 1000 lead compounds was screened against PRRSV 3CLSP using FRET assays. Preliminary screening was done at 2 μM PRRSV nsp4, 1 μM substrate and 200 μM compounds. Five compounds inhibiting more than 70% of the protease activity under these conditions were selected for further IC~50~ measurements ([Fig. 1](#fig0005){ref-type="fig"} A). These compounds, designated compounds 1--5, are shown in [Fig. 1](#fig0005){ref-type="fig"}B; their Specs ID numbers are AQ-405/42656504, AE-562/12222651, AE-562/12222652, AC-907/34117033 and AF-399/13804049, respectively ([Table 1](#tbl0005){ref-type="table"} ). Other detailed information is shown in Table S1.Fig. 1Screening inhibitors targeting PRRSV 3CLSP from a low-molecular-weight fragment-based library. Each dot represents the percentage of inhibition from compounds at concentrations of 200 μM. (A) Five compounds exhibited inhibition levels greater than 70% and were designated compounds 1--5. (B) The two-dimensional structures of compounds 1--5.Fig. 1Table 1Antiviral activity of compounds against PRRSV and PEDV.Table 1CompoundsNamePRRSV-3CL^pro^PEDV-3CL^pro^IC~50~ (μM)CC~50~[a](#tblfn0005){ref-type="table-fn"} (μM)EC~50~ (μM)SI[b](#tblfn0010){ref-type="table-fn"} valuesIC~50~ (μM)CC~50~[c](#tblfn0015){ref-type="table-fn"} (μM)EC~50~ (μM)SI values11-(3,4-difluorophenyl)-2-methyl-3,4-dihydropyrrolo\[1,2-a\]pyrazin-2-ium202.3ND\>300NDNDNDNDND2(2,4-dihydroxyphenyl) (4-methylphenyl)methanone144.3479.9578.4237.8533.81005.343(2,4-dihydroxyphenyl)(2,6-dimethylphenyl)methanone115.9482.856.88.523.4522.357.99.0244-methylpyridine147.8ND\>300ND\>500NDNDND54-(4-methylpiperidin-1-yl)quinazoline172.9738.12003.69NDNDNDND[^1][^2][^3][^4]

To evaluate their inhibitory effects on 3CLSP activity, we added different concentrations (50 μM, 100 μM, 200 μM, 300 μM, 400 μM and 500 μM) of compounds 1--5 to the protease reaction mixture, and the percentage of inhibition was calculated based on the observed fluorescence. All compounds showed concentration-dependent inhibition, with inhibition levels reaching as high as 60--80% ([Fig. 2](#fig0010){ref-type="fig"} A--E). The IC~50~ values, estimated by non-linear regression, were 202.3 μM (compound 1), 144.3 μM (compound 2), 115.9 μM (compound 3), 147.8 μM (compound 4) and 172.9 μM (compound 5). Meanwhile, the effects of DMSO on 3CSLP activity were also determined (Fig. S1). Interestingly, 3CSLP activity exhibited a concentration-dependent trend along with increased DMSO concentration (1--10%), which may lead to the high IC~50~ values.Fig. 2Effects of compounds 1--5 on the activity of PRRSV 3CLSP in a FRET assay. Enzymatic activity was measured using substrate at 1 μM and compounds 1--5 at various concentrations (12.5--500 μM). Percentage of inhibition (%) = 100 × \[1 − RFU of the experimental group (60 min--0 min)/RFU of the control group (60 min--0 min)\]. IC~50~ was determined using GraphPad Prism software 5. Bars represent the SD from three replicates.Fig. 2

3.2. Suppression of PRRSV replication by compounds 2, 3 and 5 {#sec0070}
-------------------------------------------------------------

To evaluate the suppression of PRRSV replication by compounds 2, 3 and 5, we added each compound to PRRSV-infected cells over a range of concentrations (6.25 μM, 12.5 μM, 25 μM, 50 μM, 100 μM and 200 μM). The EC~50~ values of compounds 2, 3 and 5 were estimated at 57 μM, 56.8 μM and 200 μM, respectively ([Fig. 3](#fig0015){ref-type="fig"} B). Furthermore, all three compounds showed low cytotoxicity. The CC~50~ values of compounds 2 and 3 were estimated at 479.9 μM and 482.8 μM ([Fig. 3](#fig0015){ref-type="fig"}A), respectively, whereas cell viability was higher than 60% in the presence of compound 5 at 500 μM ([Fig. 3](#fig0015){ref-type="fig"}A). Although significant cytotoxicity was observed at concentrations higher than 200 μM, compounds 2 and 3 strongly inhibited PRRSV infection at 100 μM ([Fig. 3](#fig0015){ref-type="fig"}A and B). Hence, our results showed that compounds 2 and 3 significantly inhibited PRRSV replication at non-cytotoxic concentrations (the S.I. values were approximately 8.42 and 8.5, respectively) ([Table 1](#tbl0005){ref-type="table"}). Interestingly, we observed that the EC~50~ was higher than the IC~50~, which may be due to the presence of a membrane barrier or the high protease concentration (1 μM) used in the FRET assay, as previously reported ([@bib0065]).Fig. 3Effects of compounds 2, 3 and 5 on PRRSV replication in MARC-145 cells. (A) Cell viability analysis of compounds 2, 3 and 5 (50--500 μM) in MARC-145 cells. (B) Compounds 2 and 3 inhibit PRRSV replication in MARC-145 cells. PRRSV was added with increasing concentrations of compounds (6.25 μM, 12.5 μM, 25 μM, 50 μM, 100 μM and 200 μM) at an MOI of 0.1, and then infected MARC-145 cells for 36 h. Then, the harvested supernatant (include PRRSV and compounds) was used for TCID~50~ assays. (C) Dose-dependent inhibition of PRRSV nucleocapsid protein production by compounds 2, 3 and 5. MARC-145 cells were treated with 0.4% DMSO as a control, and GAPDH was loaded as an internal control. Meanwhile, PRRSV N protein levels were normalized to GAPDH. CC~50~ and EC~50~ were determined using GraphPad Prism software 5. Bars represent the SD from three replicates. \*, P \< 0.05 (considered significant compared with control group); \*\*, P \< 0.01 (considered highly significant); \*\*\*, P \< 0.001 (considered extremely significant).Fig. 3

To further quantify the inhibitory effects of compounds 1--5, we detected PRRSV nucleocapsid (N) protein expression by western blot ([Fig. 3](#fig0015){ref-type="fig"}C). PRRSV N protein was decreased by compounds 2, 3 and 5 in a dose-dependent manner. Notably, no viral N protein was detectable in the presence of compounds 2 and 3 at 100 μM, which indicated that these compounds markedly inhibited PRRSV propagation in MARC-145 cells. Compounds 1 and 4 did not substantially suppress PRRSV replication ([Fig. 3](#fig0015){ref-type="fig"}C); differences in their molecular structures may cause weak inhibitory effects on PRRSV replication.

3.3. The broad spectrum antiviral activity of compounds 2 and 3 extends to PEDV nsp5 (3CL protease) {#sec0075}
---------------------------------------------------------------------------------------------------

PRRSV and PEDV belong to the order *Nidovirales* and possess similarities in genome organization and strategies for nonstructural and structural protein expression ([@bib0175]). Hence, we evaluated the inhibitory effects of compounds 2 and 3 on PEDV 3CL protease activity in the FRET assay. Both compounds showed concentration-dependent inhibition, with inhibition levels reaching as high as 80% ([Fig. 4](#fig0020){ref-type="fig"} A). The IC~50~ values were 37.8 μM (compound 2) and 23.4 μM (compound 3), as estimated by non-linear regression. Meanwhile, the ability of compounds 2 and 3 to block PEDV replication was also evaluated. The PEDV strain was sensitive to both compounds with EC~50~ values of 100 μM and 57.9 μM, respectively ([Fig. 4](#fig0020){ref-type="fig"}C), and PEDV N protein was decreased by compounds 2 and 3 in a dose-dependent manner ([Fig. 4](#fig0020){ref-type="fig"}D). Furthermore, CC~50~ values measured in Vero cells were 533.8 μM and 522.3 μM ([Fig. 4](#fig0020){ref-type="fig"}B), and the S.I. values were approximately 5.34 and 9.02 ([Table 1](#tbl0005){ref-type="table"}), respectively. Additionally, our results showed that the protease activity of EAV 3CLSP was inhibited by compound 3 (Fig. S1). Therefore, compounds 2 and 3 behave as potential broad-spectrum antiviral agents.Fig. 4Broad-spectrum inhibition of compounds 2 and 3 against PEDV. (A) Effects of compounds 2 and 3 on the 3CL protease activity of PEDV in a FRET assay. Compounds at various concentrations (12.5--500 μM) were pre-incubated with protease for 20 min at 37 °C, and the fluorescence values was measured. Percentage of inhibition was calculated as in [Fig. 2](#fig0010){ref-type="fig"}. (B) Cell viability analysis of compounds 2 and 3 (50--500 μM) in Vero cells. (C) Compounds 2 and 3 inhibit PEDV replication in Vero cells. TCID~50~ assay for PEDV was performed as in [Fig. 3](#fig0015){ref-type="fig"}B. (D) Dose-dependent inhibition of PEDV nucleocapsid protein production by compounds 2 and 3. Vero cells were treated with 0.4% DMSO as a control, and GAPDH was loaded as an internal control. Meanwhile, PEDV N protein levels were normalized to GAPDH. IC~50~, CC~50~ and EC~50~ were determined using GraphPad Prism software 5. Bars represent the SD from three replicates. \*, P \< 0.05 (considered significant compared with control group); \*\*, P \< 0.01 (considered highly significant); \*\*\*, P \< 0.001 (considered extremely significant).Fig. 4

3.4. Potential binding sites {#sec0080}
----------------------------

The complex crystal structures of protein-compounds are used to guide the organic synthesis of high-affinity protein ligands and enzyme inhibitors ([@bib0020]). In this study, we soaked PRRSV 3CLSP and PEDV 3CL protease crystals with various concentrations of compounds 2 and 3. Unfortunately, we were unable to obtain complex structures. Therefore, the potential binding sites were analyzed in detail using molecular simulations to dock compounds 2 and 3 into the PRRSV 3CLSP and PEDV 3CL protease structures ([Fig. 5](#fig0025){ref-type="fig"} A and B). The complex models were initially positioned based on the X-ray structures (Streptomyces griseus proteinase E, SGPE, PDB code: [1HPG](pdb:1HPG){#intr0040}; PEDV nsp5: [4ZUH](pdb:4ZUH){#intr0045}) ([@bib0090], [@bib0170]). Grid maps of 40 × 40 × 40 grid points, centered on the substrates of the complex structures, covered the binding pockets. A population size of 150, mutation rate of 0.02, and crossover rate of 0.8 were set as the parameters. Simulations were performed using up to 2.5 million energy evaluations with a maximum of 27,000 generations. Each simulation was performed 100 times, yielding 256 docked conformations. The lowest energy conformations were regarded as the binding conformations between the ligands and the proteins ([@bib0150]). In the complex models, compounds 2 and 3 interacted with 3CLSP/3CL proteases via extensive hydrogen bonds and hydrophobic forces ([Fig. 5](#fig0025){ref-type="fig"}A and B).Fig. 5Docking of compounds 2 and 3 with PRRSV 3CLSP (nsp4) and PEDV 3CL protease (nsp5). (A) Docked conformations of compounds 2 and 3 with PRRSV nsp4. The compounds and amino acid residues contacting the compounds are represented as sticks and lines, respectively (the protease surface transparency is set at 40%). The amino acid residues are colored according to atom type. Moreover, hydrogen bond interactions are shown as black dashed lines between the respective donor and acceptor atoms, along with the bond distance. (B) Docked conformations of compounds 2 and 3 with PEDV nsp5. The compounds and molecular interactions are represented as in A. (C) Sequence relationships between arterivirus 3CLSP and coronavirus 3CL protease. The amino acid sequence of EAV (GenBank: X53459.3) nsp4 was used for sequence relationship analysis. The residue numbers at the top refer to the PRRSV 3CLSP amino acid sequence. The key residues for potential 3CLSP activity sites and substrate binding sites on PRRSV are marked with red arrows at the bottom. The sequences were aligned using ClustalW2, and the alignment was drawn with ESPript 3.0. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 5

The active sites of the PRRSV nsp4 consist of His39, Asp64 and Ser118; additionally, the S1 specificity pocket is conserved in *artertiviruses* (PRRSV and EAV) and comprises His133 and Ser136 (corresponding to His134 and His137 of EAV nsp4) ([Fig. 5](#fig0025){ref-type="fig"}C) ([@bib0125]). Indeed, the active sites (His39, Asp64 and Ser118) and S1 specificity pocket (His133 and Ser136) of PRRSV nsp4 interacted with compounds 2 and 3 via hydrogen bonds and hydrophobic forces ([Fig. 5](#fig0025){ref-type="fig"}A). In PEDV, the active sites of the nsp5 was composed of His41 and Cys144, and the S1 specificity pocket consists of Phe139, Ile140, Asn141, Gly142, Ala143, Cys144, His162, Gln163 and Glu165 ([@bib0170]). Analogously, extensive interactions among compounds 2, 3 and the active site (His41) and S1 specificity pocket (Glu165) of the PEDVnsp5 were also observed ([Fig. 5](#fig0025){ref-type="fig"}B). Hence, compounds 2 and 3 may block the recognition and combination of the 3CLSP/3CL proteases and substrates, thereby inhibiting PRRSV and PEDV replication.

Multiple-sequence alignment indicated that the amino acid sequence identity between PRRSV nsp4 and PEDV nsp5 was approximately only 22.2% ([Fig. 5](#fig0025){ref-type="fig"}C). Moreover, there were distinct differences between the structures of the 3CLSP and 3CL protease (RSMD is 2.66). Interestingly, the active site His39 in PRRSV nsp4 (corresponding to His41 of PEDV nsp5) is conservative ([Fig. 5](#fig0025){ref-type="fig"}C). Meanwhile, these two sites contact compounds 2 and 3 via hydrogen bonds and hydrophobic forces ([Fig. 5](#fig0025){ref-type="fig"}A and B), which may be the reason that compounds 2 and 3 exhibit broad-spectrum activity against PRRSV and PEDV.

4. Discussion {#sec0085}
=============

Porcine reproductive and respiratory syndrome virus (PRRSV) and porcine epidemic diarrhea virus (PEDV) are major threats to the worldwide swine industry. Currently, both inactivated and live attenuated virus vaccines have been used in the intensive pig farm. Although reducing mortality, the currently used vaccines cannot to control PRRSV and PEDV infection and spread. Furthermore, no commercial drugs are available to prevent their infection. For *Nidoviruses*, the 3CLSP and 3CL protease are key players in viral replication ([@bib0165]). Hence, the development of anti-viral drugs targeting the 3CLSP and 3CL proteases would become an important strategy for preventing PRRSV and PEDV outbreaks.

In our experiment, the compounds screening targeting 3CLSP and 3CL protease was used to identify inhibitors that suppress PRRSV and PEDV replication. Meanwhile, to elucidate the binding mechanism of compounds and 3CLSP or 3CL proteases, we simulated the most likely binding conformations using Autodock 4 software. In the 3CLSP and 3CL protease, the S1 specificity pocket is essential for recognition of the side chain of the substrate P1 residue and determination of the enzyme's preference ([@bib0125], [@bib0170]). Hence, the residues of S1 specificity pockets were selected as targets for molecule docking. A total of 256 binding conformations between the ligands and the proteins were obtained, and the lowest energy conformations were used for further analysis. As shown in [Fig. 5](#fig0025){ref-type="fig"}A and B, compounds 2 and 3 are illustrated as sticks, and the amino acid residues contacting the compounds are shown as lines. Because there is a significant difference in the residues of S1 specificity pockets between PRRSV nsp4 and PEDV nsp5, compounds 2 and 3 were docked into 3CLSP and 3CL protease with different conformations and interactions ([Fig. 5](#fig0025){ref-type="fig"}A and B). Besides, due to the semi-flexible docking was performed, the binding conformations of compounds 2 and 3 with 3CLSP or 3CL protease also exists subtle differences. Nonetheless, their interactions are highly similar ([Fig. 5](#fig0025){ref-type="fig"}A and B). Otherwise, previous studies have shown that the substrate-binding sites and active sites of the 3CLSP and 3CL protease are located between domains I and II in their structures ([@bib0125], [@bib0170]). The amino acid residue His39 in 3CLSP (corresponding to His41 of 3CL protease) plays a vital role in substrate combination and catalysis. Indeed, our docking analysis results suggested that compounds 2 and 3 bind in the substrate channel between domains I and II, which form strongly hydrophobic interactions and hydrogen bonds with His39 (or His41) ([Fig. 5](#fig0025){ref-type="fig"}A). Hence, compounds 2 and 3 would be broad competitive inhibitors and bind in the substrate-binding channel of the 3CLSP and 3CL protease, replacing the substrate.

Additionally, our results showed that compounds 2 and 3 could effectively inhibit the replication of PRRSV and PEDV at a micromolar range. Unfortunately, their EC~50~ values were high (\>50 μM), and the selectivity index (SI) values were less than 10 ([Fig. 3](#fig0015){ref-type="fig"}, [Fig. 4](#fig0020){ref-type="fig"}; [Table 1](#tbl0005){ref-type="table"}). As lead compounds, compounds 2 and 3 have a low molecular weight (\<250 Da) (Table S1). Thus, further medicinal chemistry optimization is available to increase the selectivity index and pharmacokinetic properties (DMPK). Moreover, the substrate-binding channel of the 3CLSP or 3CL protease is a large cavity, supplementary studies may need to more accurately characterize the compound-binding sites to design and optimize inhibitors. For Norwalk virus and feline coronavirus, the transition state 3C-like protease inhibitors were designed and synthesized, and exhibited notable inhibitory effects against viral replication ([@bib0135], [@bib0060]). Therefore, transition state compounds that will optimally generate hydrophobic interactions and hydrogen bonds with the side chain amino acid residues are needed, and animal studies should also be conducted to develop antiviral drugs against PRRSV and PEDV in the future. Finally, our results emphasize the feasibility of developing anti-PRRSV and anti-PEDV inhibitors as a new class of broad-spectrum antiviral drugs as a treatment for exposure to viral agents.

5. Conclusions {#sec0090}
==============

The emerging, highly virulent PRRSV and PEDV strains have been widespread and prevalent worldwide, and seriously affect and constrain the development of the pig farming industry. In this study, we identified novel antiviral inhibitors that target PRRSV nsp4 (3CLSP), which were designated compounds 2 and 3. These two compounds could substantially inhibit PRRSV replication. Moreover, compounds 2 and 3 exhibited broad-spectrum antiviral activities, which target the PEDV 3CL protease and inhibit PEDV replication. Our results will help to guide the development of new broad-spectrum antiviral drugs against PRRSV and PEDV.
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[^1]: ND: Not determined.

[^2]: 50% cytotoxic concentration in MARC-145 cells.

[^3]: selectivity index (SI) values.

[^4]: 50% cytotoxic concentration in Vero cells.
